MIM
TARS icon

Monashee Investment Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Monashee Investment Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$1.82M – 134
2024
Q1 		$1.82M Buy
+50,000
New +$1.47M 0.22% 75

Other funds holding TARS

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Monashee Investment Management's TARS Position: Q2 2024 in Review

Monashee Investment Management sold out of Tarsus Pharmaceuticals (TARS) in Q2 2024, closing a stake of 50,000 shares — an estimated $1.82M sold.

Monashee Investment Management first reported a position in TARS in Q1 2024 and held it in 1 quarter. The position peaked at $1.82M in Q1 2024. 148 funds tracked by Wall St. Rank hold TARS as of Q2 2024.

  • Monashee Investment Management reported no remaining Tarsus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Monashee Investment Management sold 50,000 Tarsus Pharmaceuticals shares in Q2 2024, an estimated $1.82M.
  • Monashee Investment Management first reported a position in Tarsus Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Monashee Investment Management's Tarsus Pharmaceuticals position peaked at $1.82M in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2024.

Based on Monashee Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.